Speaker Spotlight – National Conference Edition Part 11

drhowe

James R. Howe V, MD

uofiowaclinic

Bio:

Director, Division of Surgical Oncology and Endocrine Surgery

Co-Director, Neuroendocrine Cancer Clinic

Professor of Surgery  – Surgical Oncology and Endocrine Surgery

Education:

MD, University of Vermont College of Medicine

Fellowship, Surgical Research Fellow, Washington University

Residency, General Surgery, Barnes Hospital

Fellowship, Clinical, Surgical Oncology, Memorial Sloan-Kettering Center

Licensure and Certifications:

Iowa Medical License, Iowa Board of Medicine

Certified, Advanced Trauma Life Support

Board Certified, General Surgery, American Board of Surgery

Qualifying Examination, American Board of Surgery

Recertification Examination, American Board of Surgery

Research Summary:

I am a Surgical Oncologist and Endocrine Surgeon who specializes in taking care of patients with cancers of the pancreas, liver, GI tract, soft tissue sarcoma, melanoma, thyroid, parathyroid, and adrenal glands; I am co-director of the neuroendocrine cancer clinic, Division Director of Surgical Oncology and Endocrine Surgery, and Professor of Surgery at the University of Iowa. My area of research expertise is in Familial Cancer Syndromes, genetic linkage, gene discovery, and gene expression studies. My postdoctoral training at Washington University under Helen Donis-Keller, Ph.D. and Samuel Wells, M.D., was directed at the identification of the gene for Multiple Endocrine Neoplasia Type 2. As a faculty member, my focus has been the genetics of Juvenile Polyposis, which led to the discovery of the 2 predisposing genes. More recently, I have developed a large clinical practice and research interest in the genetics of neuroendocrine tumors (NETs). Our current research focus is the study of gene expression profiles in pancreatic and small bowel NETs to identify new targets for imaging and treatment, and collection of families to search for predisposing genes.

For more information on Dr. James Howe and the University of Iowa Hospitals and Clinics, please visit their website here. You can also view Dr. Howe’s academic profile, here.

You can read Dr. Howe’s publications by clicking here.

For information on the Neuroendocrine Cancer Program at the University of Iowa Hospitals and Clinics, you can find that here.

To make an appointment, please contact:

University of Iowa Hospitals and Clinics: 200 Hawkins Drive, Iowa City, IA 52242

Phone: (800) 777-8442 or (319) 356-1727

Dr. Howe at the 2016 National NET Patient Conference:

Topic: Hepatic Resection vs Liver Directed Therapy

When: Saturday, September 24th, 2016 at 8:30AM*

SIGN UP NOW FOR THE 2016 NATIONAL NET PATIENT CONFERENCE in New Orleans, LA from September 22-24th to see Dr. Howe and 19 other experts speak on Neuroendocrine Cancer! 

Registration is $125 per person including

  • Thursday’s Welcome Reception 
  • Breakfast, Lunch, and snacks for both Friday and Saturday
  • And keep your eyes out for some special prizes!

Registration does not include your hotel stay or travel expenses.

For more information and to buy your ticket, click here!!

*Time and Date are subject to change.

To check out some of our other speakers, click here!

The Speaker Spotlight – 2016 National Conference Edition Part 5

O'Dorisio

Thomas O’Dorisio, MD

Professor of Medicine, Director of the Neuroendocrine Tumor Clinics Program

UIhosplogo

Bio:

Dr. Thomas O’Dorisio is Professor of Medicine and Director of the Neuroendocrine Tumor Clinics Program in the Holden Comprehensive Cancer Center at the University of Iowa.   Currently 1700 patients with carcinoid and familial/sporadic neuroendocrine tumors in both children and adults are registered via an IRB approved consent form.  With Co-directors Dr. James R. Howe (Endocrine surgeon) and Dr. M. Sue O’Dorisio (Pediatric Oncology), there are seven dedicated multi-disciplinary neuroendocrine tumor clinics weekly that include a neuroendocrine tumor clinic for the Veterans Administration Hospital.  Multi- diagnostic and therapeutic modalities for these patients include the highly sensitive and specific 68-Gallium – DOTATOC PET scan.  We are currently analyzing the safety and efficacy data of 200 subjects who have had this scan.  Therapeutic advances include the registration trial of LU-177 –DOTA-Octretoate therapy, a multi-international institution protocol for progressive midgut carcinoid tumors.  We anticipate the first peptide receptor radio-nuclide therapy (PRRNT) Phase II trial in the United States with Y90-DOTA-(tyr)-Octreotide within the next two months.  We see between 16 and 24 new neuroendocrine patients monthly, and have 900-1200 neuroendocrine patient visits per year. Our Clinical-Clinical Research Center is modeled after the 21 or so European NET Centers of Excellence, dedicated to this rare cancer with a prevalence in the United States of about 110,000 patients and an incidence since 1989 that has risen by 500%.

To see his official University of Iowa Heath Care video profile, please click here.

Education:

BS, Regis College, Denver, Colorado

MS, Anatomy, Creighton University, Omaha, Nebraska

MD, Creighton University, Omaha, Nebraska

Internship, Internal Medicine, Creighton University

Residency, Internal Medicine, The Ohio State University, Columbus, Ohio

Fellowship, Endocrinology, The Ohio State University, Columbus, Ohio

Licensure and Certifications:

Medical License, Iowa Board of Medicine

Certification, The College of American Pathologists (CAP) Ohio

Certification of Accreditation, Department of Health & Human Services Health Care Financing Administration (HCFA) CLIA Laboratory

Certification, American Board of Internal Medicine

To make an appointment as a NEW patient, please call:

The Holden Comprehensive Cancer Center at the University of Iowa                        (319) 356-4200 Option #3, Ask for Molly Becker

University of Iowa Hospitals and Clinics                                                                       200 Hawkins Drive                                                                                                                    Iowa City, IA 52242                                                                                                                 (800) 777-8442

Dr. O’Dorisio at the 2016 National NET Patient Conference:

Topic: PRRT Trials in America: What’s New?

When: Friday, September 23rd, 2016 at 1PM*

Be sure not to miss Dr. O’Dorisio speak! And don’t miss him on our panel answering your questions!!

For more information on Dr. O’Dorisio and the Holden Comprehensive Cancer Center at the University of Iowa, please visit their website here.

SIGN UP NOW FOR THE 2016 NATIONAL NET PATIENT CONFERENCE in New Orleans, LA from September 22-24th to see Dr. O’Dorisio and 19 other experts speak on Neuroendocrine Cancer! 

Registration is $125 per person including

  • Thursday’s Welcome Reception 
  • Breakfast, Lunch, and snacks for both Friday and Saturday
  • And keep your eyes out for some special prizes!

Registration does not include your hotel stay or travel expenses.

For more information and to buy your ticket, click here!!

*Time and Date are subject to change.